期刊
JOURNAL OF MATERIALS CHEMISTRY B
卷 10, 期 4, 页码 607-624出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/d1tb01455b
关键词
-
资金
- National Natural Science Foundation of China [31971301, 31971242, 12032007]
- Fundamental Research Funds for Central Universities [2020CDJQY-A061, 2018CDHB1B08]
- Chongqing Research Program of Basic research and Frontier Technology [cstc2019jcyj-zdxmX0028]
Nitric oxide (NO) plays a crucial role in atherosclerosis management, and the PLGA-LA/LV nanomedicine demonstrated its potential to enhance NO production in vitro and in vivo, showing promising results for AS treatment.
Nitric oxide (NO) is an exceptional endogenous biological gas that mediates and regulates physiological and pathological processes in the human body. However, its synthesis process is impaired during athero-progression and formation. Hence, a strategy to boost NO production and target endothelial nitric oxide synthase (eNOS) is crucial and intriguing in atherosclerosis (AS) management. Herein, we prepare l-arginine (LA) and lovastatin (LV) co-loaded PLGA nanomedicine to achieve sustainable release for enhancing NO production. The utilization of LA reveals that LA has dual contributions, acting as a NO donor and enhancing the solubility of LV by stabilizing PLGA NPs. PLGA-LA/LV demonstrated its potential to boost NO in vitro and in vivo confirmed using DAF-FM DA, augment eNOS and p-eNOS mRNA and protein levels, and suppress the ki67 proliferation marker in VSMCs; in addition, it lowers the total cholesterol level of blood plasma in C57BL/6 mice. Moreover, PLGA can protect the compound delivered and enhance the bioavailability to reach and get released in the blood circulation after oral administration. Collectively, our results endow a safe and efficient nanomedicine outcome, specifically with potential for AS management.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据